1. Lam CG, Howard SC, Bouffet E, Pritchard-Jones K. Science and health for all children with cancer. Science. 2019;363(6432):1182-1186.

2. Bhakta N, Force LM, Allemani C, et al. Childhood cancer burden: a review of global estimates. Lancet Oncol. 2019;20(1):e42-e53.

3. Howard SC, Davidson A, Luna‐Fineman S, et al. A framework to develop adapted treatment regimens to manage pediatric cancer in low‐ and middle‐income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatric Blood & Cancer. 2018;64(S5):e26879.

4. Hesseling P, Israels T, Harif M, Chantada G, Molyneux E, Pediatric Oncology in Developing C. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer. 2013;60(3):357-362.

5. Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low‐income countries: A proposal. Pediatric Blood & Cancer. 2009;52(5):559 565.

6. Chantada GL, Fandino AC, Guitter MR, et al. Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer. 2010;55(1):60-66.

7. Israels T, Moreira C, Scanlan T, et al. SIOP PODC: Clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatric Blood & Cancer. 2013;60(1):5-11.

8. Hessissen L, Parkes J, Amayiri N, et al. SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatric Blood & Cancer. 2018;64(S5):e26737.

9. Bouffet E, Challinor J, Sullivan M, Biondi A, Rodriguez-Galindo C, Pritchard-Jones K. Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatric Blood and Cancer. 2020;In press.

10. Balduzzi A, Brivio E, Rovelli A, et al. Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hematooncology center embedded within a COVID-19 dedicated hospital in Lombardia. Bone Marrow Transplant. 2020;in press. 11. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. Acta Paediatr Oslo Nor 1992. 2020.

11. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics. 2020:e20200702.

12. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. New Engl J Medicine. 2020;382(14):1370-1371.

13. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. New Engl J Medicine. 2020.

14. Rasmussen SA, Thompson LA. Coronavirus Disease 2019 and Children. JAMA Pediatrics. 2020;174(8).

15. Hrusak O, Kalina T, Wolf J, et al. Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment. European Journal of Cancer. 2020;in press.

16. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020.

17. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State. J Pediatric Infect Dis Soc. 2019;8(1):21-28.

18. Ogimi C, Greninger AL, Waghmare AA, et al. Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution. J Infect Dis. 2017;216(2):203-209.

19. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127(22):2682-2692.

20. Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020.

21. Vaitkeviciene G, Heyman M, Jonsson OG, et al. Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. Leukemia. 2013;27(11):2259-2262.

22. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. Journal of Clinical Oncology. 1996;14(1):18-24.

23. Israels T, van de Wetering MD, Hesseling P, van Geloven N, Caron HN, Molyneux EM. Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi. Pediatr Blood Cancer. 2009;53(1):47-52.

24. Molyneux EM, Rochford R, Griffin B, et al. Burkitt’s lymphoma. Lancet. 2012;379(9822):1234-1244.

25. Bhethanabhotla S, Jain S, Kapoor G, et al. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma. 2017;58(7):1617-1623.

26. Marr KC, Connors JM, Savage KJ, Goddard KJ, Deyell RJ. ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma. Ann Oncol. 2017;28(4):849-854.

27. Mauz-Korholz C, Metzger ML, Kelly KM, et al. Pediatric Hodgkin Lymphoma. J Clin Oncol. 2015;33(27):2975-2985.

28. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399-408.

29. Hessissen L, Khtar R, Madani A, et al. Improving the prognosis of pediatric Hodgkin lymphoma in developing countries: a Moroccan Society of Pediatric Hematology and Oncology study. Pediatr Blood Cancer. 2013;60(9):1464-1469.

30. Arya LS, Dinand V, Thavaraj V, et al. Hodgkin’s disease in Indian children: outcome with chemotherapy alone. Pediatr Blood Cancer. 2006;46(1):26-34.

31. Parambil BC, Narula G, Prasad M, et al. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India. Pediatr Blood Cancer. 2020;67(2):e28058.

32. Chevez-Barrios P, Eagle RC, Jr., Krailo M, et al. Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children’s Oncology Group Study. J Clin Oncol. 2019;37(31):2883-2891.

33. Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31(11):1458-1463.

34. Chantada G, Luna-Fineman S, Sitorus RS, et al. SIOP- PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatric Blood & Cancer. 2013;60(5):719 727.

35. Choucair ML, Brisse HJ, Freneaux P, et al. Management of advanced uni- or bilateral retinoblastoma with macroscopic optic nerve invasion. Pediatr Blood Cancer. 2020;67(1):e27998.

36. Luna-Fineman S, Chantada G, Alejos A, et al. Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. J Clin Oncol. 2019;37(31):2875-2882.

37. Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012;379(9824):1436-1446.

38. Perez V, Sampor C, Rey G, et al. Treatment of Nonmetastatic Unilateral Retinoblastoma in Children. JAMA Ophthalmol. 2018;136(7):747-752.

39. Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. Journal of Clinical Oncology. 2015;33(27):2999-3007.

40. Heuvel-Eibrink MMvd, Hol JA, Pritchard-Jones K, et al. Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol. Nat Rev Urol. 2017;14(12):743-752.

41. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2641-2647.

42. Dodgshun AJ, Maixner WJ, Heath JA, Sullivan MJ, Hansford JR. Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy. Int J Cancer. 2016;138(2):481-488.

43. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337.

44. Krengli M, Ferrara, Eleonora., Mastroleo, Federico ., Brambilla,Marco ., Ricard, Umberto . Running a Radiation Oncology Department at the time of coronavirus: an Italian experience. Advances in Radiation Oncology. 2020;in press.

45. Simcock R, Thomas TV, Estes C, et al. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020;22:55-68.

46. Achard V, Tsoutsou P, Zilli T. Radiotherapy in the time of the Coronavirus pandemic: when less is better. Int J Radiat Oncol Biol Phys. 2020.

47. Filippi AR, Russi E, Magrini SM, Corvo R. Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. Int J Radiat Oncol Biol Phys. 2020.

48. NICE Guidance. C-. COVID-19 rapid guideline:delivery of radiotherapy. In: https://www.nice.org.uk/guidance/NG162; 2020.

49. Slotman B, Ricardi, Umberto., Lievens, Yolande.,. “Radiotherapy in a time of crisis”, ESTRO Presidents statement. 2020; https://www.estro.org/About/Newsroom/News/Radiotherapy-in-a-time-of-crisis.

50. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review. Plos One. 2012;7(4):e35797.

51. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intens Care Med. 2020:1-34.

52. Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19. Anaesthesia. 2020.

53. Spinelli A, Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. Br J Surg. 2020.

54. Powell RA, Schwartz L, Nouvet E, et al. Palliative care in humanitarian crises: always something to offer. Lancet. 2017;389(10078):1498-1499.

55. Adams JG, Walls RM. Supporting the Health Care Workforce During the COVID-19 Global Epidemic. JAMA. 2020.

56. Center for Disease Control and Prevention (USA). Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID19) in healthcare settings. 2020; https://www.cdc.gov/coronavirus/2019-ncov/hcp/infectioncontrol-recommendations.html. . Accessed April 20, 2020.

57. Soucheray S. Three more health workers infected in Ebola outbreak. Center for Infectious Disease Research and Policy2019.

58. Costa JT, Silva R, Tavares M, Nienhaus A. High effectiveness of pandemic influenza A (H1N1) vaccination in healthcare workers from a Portuguese hospital. Int Arch Occup Environ Health. 2012;85(7):747-752.

59. McDiarmid M. Advocating for the Health Worker. Ann Glob Health. 2019;85(1).

60. Maunder RG, Leszcz M, Savage D, et al. Applying the lessons of SARS to pandemic influenza: an evidence-based approach to mitigating the stress experienced by healthcare workers. Can J Public Health. 2008;99(6):486-488.

61. World Health Organisation (Geneva). Water, sanitation, hygiene and waste management for COVID-19 virus. Technical brief 3 March 2020. . 2020; https://apps.who.int/iris/bitstream/handle/10665/331305/WHO-2019-NcOV-IPC_WASH-2020.1-eng.pdf. Accessed 7 April, 2020.

62. European Centre for Disease Prevention and Control. Using Face Masks in the Community; Reducing COVI-19 transmission from potentially asymptomatic or presymptomatic people through the use of face masks: Technical Report 8 April 2020. 8 April 2020 2020.

63. Fisher EM, Shaffer RE. Considerations for recommending extended use and limited reuse of filtering facepiece respirators in health care settings. Journal of occupational and environmental hygiene. 2014;11(8):D115-128.

64. World Health Organisation (Geneva). Advice on the use of masks in the context of COVID-19: Interim guidance , 6 April 2020. 6 April 2020 2020.

65. Cross AR. During coronavirus outbreak, Red Cross mission continues: We need your help. 2020; www.redcross.org/local/south-carolina/aboutus/news-and-events/press-releases/during-coronavirus-outbreak--red-cross-mission-continues---we-ne.html. . Accessed Accessed April 18, 2020.

66. World Health Organsiation. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19) WHO Interim guidance, March 2020. 2020; https://www.who.int/publications-detail/maintaining-a-safe-and-adequatebloodsupply-during-the-pandemic-outbreak-of-coronavirus-disease-(covid-19). Accessed April 18, 2020.

67. Schiffer CA, Bohlke K, Delaney M, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(3):283-299.

68. Food and Drug Administration (USA) DoHaHS, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER),, Center for Biologics Evaluation and Research (CBER) CfDaRHC, Oncology Center of Excellence (OCE), Office of Good Clinical Practice (OGCP). FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional, Review Boards. March 2020, updated April 16 2020 2020.

69. Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (USA). Coronavirus Guidance: DCTD CTEP and NCORP Guidances. 2020; https://ctep.cancer.gov/investigatorResources/corona_virus_guidance.htm. Accessed 22 April, 2020.

70. European Medicines Agency (EMA). Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic, version 2, 27/3 2020. 27 March 2020 2020.

71. St Jude Global C-OaRC. The Global COVID-19 Observatory and Resource Center for Childhood Cancer. 2020; https://global.stjude.org/en-us/global-covid-19-observatory-and-resource-center-for-childhood-cancer.html. Accessed 22 April, 2020.

72. Global COVID-19 Registry. St Jude Childrens Research Hospital; 2020. https://global.stjude.org/en-us/global-covid-19-observatory-andresource-center-for-childhood-cancer.html. Accessed 22 April 2020.

73. IGHG COVID-19 statement, https://www.ighg.org/ accessed 22 April 2020.

74. Rasmussen SA, Thompson LA. Coronavirus Disease 2019 and Children. JAMA Pediatrics. 2020;174(8).

75. Hrusak O, Kalina T, Wolf J, et al. Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment. European Journal of Cancer. 2020;in press.

76. Vaitkeviciene G, Heyman M, Jonsson OG, et al. Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. Leukemia. 2013;27(11):2259-2262.

77. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. Journal of Clinical Oncology. 1996;14(1):18-24.

78. S Yetgin NYO, G Masera, M G Valsecchi, Dacou-Voutetakis, L Loening, M Schrappe, M Zimmermann, G Henze, A von Stackelberg, H Gadner, G Mann, A Attarbaschi, S R Brandalise, W L Carroll, P Gaynon, J M Boyett, J Nachman, M Devidas, H N Sather, G Escherich, G Janka, R D Gelber, S E Sallan, R Pieters, M Bierings, W A Kamps, J Otten, S Suciu, M B Viana, A Baruchel, M Auclerc, C Perez, A Solidaro, B Stark, D Steinberg, S Koizumi, M Tsurusawa, F Zintl, I Schiller, A Matsuzaki, T O B Eden, J S Lilleyman, S Richards, P G Steinherz, L Steinherz, V Kochupillai, S Bakhshi, J J Ortega, J Nachman, F R Appelbaum, C Cheng, D Pei, C H Pui, P Kukure, S Nakazawa, M Tsuchida, T Elphinstone, V Evans, L Gettins, C Hicks, L MacKinnon, P Morris, S Richards, R Wade. Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol. 2009;145(3):376-388.

79. Teuffel O, Kuster SP, Hunger SP, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011;25(8):1232-1238.

80. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21(9):1798-1809.

81. Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. J Clin Oncol. 2019;37(19):1638-1646.

82. Schmiegelow K, Nersting J, Nielsen SN, et al. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer. 2016;63(12):2104-2111.

83. Harms DO, Gobel U, Spaar HJ, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood. 2003;102(8):2736-2740.

84. Eden T, Pieters R, Richards S, Childhood Acute Lymphoblastic Leukaemia Collaborative G. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data metaanalysis involving 5,659 children. Br J Haematol. 2010;149(5):722-733.

85. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet. 2007;369(9556):123-131.

86. Vora A, Andreano A, Pui CH, et al. Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. J Clin Oncol. 2016;34(9):919-926.

87. Hesseling P, Israels T, Harif M, Chantada G, Molyneux E, Pediatric Oncology in Developing C. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer. 2013;60(3):357-362.

88. Israels T, van de Wetering MD, Hesseling P, van Geloven N, Caron HN, Molyneux EM. Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi. Pediatr Blood Cancer. 2009;53(1):47-52.

89. Molyneux EM, Rochford R, Griffin B, et al. Burkitt’s lymphoma. Lancet. 2012;379(9822):1234-1244.

90. Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood. 2018;132(3):254-263.

91. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840-847.

92. Pena-Hernandez A, Ortiz R, Garrido C, et al. Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA). Pediatr Blood Cancer. 2019;66(5):e27621.

93. Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167(3):394-401.

94. Bouda GC, Traore F, Couitchere L, et al. Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pediatrique. J Glob Oncol. 2019;5:1-9.

95. Molyneux E, Schwalbe E, Chagaluka G, et al. The use of anthracyclines in the treatment of endemic Burkitt lymphoma. Br J Haematol. 2017;177(6):984-990.

96. Israels T, Moreira C, Scanlan T, et al. SIOP PODC: Clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatric Blood & Cancer. 2013;60(1):5-11.

97. Bhethanabhotla S, Jain S, Kapoor G, et al. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma. 2017;58(7):1617-1623.

98. Marr KC, Connors JM, Savage KJ, Goddard KJ, Deyell RJ. ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma. Ann Oncol. 2017;28(4):849-854.

99. Mauz-Korholz C, Metzger ML, Kelly KM, et al. Pediatric Hodgkin Lymphoma. J Clin Oncol. 2015;33(27):2975-2985.

100. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399-408.

101. Hessissen L, Khtar R, Madani A, et al. Improving the prognosis of pediatric Hodgkin lymphoma in developing countries: a Moroccan Society of Pediatric Hematology and Oncology study. Pediatr Blood Cancer. 2013;60(9):1464-1469.

102. Arya LS, Dinand V, Thavaraj V, et al. Hodgkin’s disease in Indian children: outcome with chemotherapy alone. Pediatr Blood Cancer. 2006;46(1):26-34.

103. Parambil BC, Narula G, Prasad M, et al. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India. Pediatr Blood Cancer. 2020;67(2):e28058.

104. Flerlage JE, Kelly KM, Beishuizen A, et al. Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement. Pediatr Blood Cancer. 2017;64(7).

105. Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28(23):3680-3686.

106. Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children’s Oncology Group. Cancer. 2018;124(15):3210-3219.

107. Fuchs M, Goergen H, Kobe C, et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835-2845.

108. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children’s Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651-3658.

109. Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. Br J Haematol. 2019;187(1):39-48.

110. Connors JM, Radford J. Letter comments on a published article in the New England Journal of Medicine. Eur J Cancer. 2018;104:250-251.

111. Ingley KM, Nadel HR, Potts JE, Wilson DC, Eftekhari A, Deyell RJ. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD. J Pediatr Hematol Oncol. 2020;42(2):e87-e93.

112. Appel BE, Chen L, Buxton AB, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children’s Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(20):2372-2379.

113. Shankar A, Visaduraki M, Hayward J, Morland B, McCarthy K, Hewitt M. Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - the results of the United Kingdom HD3 national cohort trial. Eur J Cancer. 2012;48(1):108-113.

114. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862.

115. Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin’s disease: a Children’s Oncology Group report. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology. 2009;27(9):1456-1461.

116. Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(9):1229-1238.

117. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40-48.

118. Harker-Murray PD, Leblanc T, Mascarin M, et al. Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 2018;132:927.

119. Harker-Murray PD, Thomas AJ, Wagner JE, et al. Allogeneic hematopoietic cell transplantation in children with relapsed acute

120. lymphoblastic leukemia isolated to the central nervous system. Biol Blood Marrow Transplant. 2008;14(6):685-692.

121. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35-41.

122. Trippett TM, Schwartz CL, Guillerman RP, et al. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children’s oncology group report. Pediatr Blood Cancer. 2015;62(1):60-64.

123. Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012;379(9824):1436-1446.

124. Chantada G, Luna-Fineman S, Sitorus RS, et al. SIOP- PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatric Blood & Cancer. 2013;60(5):719 727.

125. Mallipatna AC GB, Chévez-Barrios P, Lumbroso-Le Rouic L, Chantada G, Doz F, Munier FL, . Retinoblastoma; AJCC Cancer staging system. 8 ed. New York: Springer; 2018.

126. Chevez-Barrios P, Eagle RC, Jr., Krailo M, et al. Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children’s Oncology Group Study. J Clin Oncol. 2019;37(31):2883-2891.

127. Choucair ML, Brisse HJ, Freneaux P, et al. Management of advanced uni- or bilateral retinoblastoma with macroscopic optic nerve invasion. Pediatr Blood Cancer. 2020;67(1):e27998.

128. Luna-Fineman S, Chantada G, Alejos A, et al. Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. J Clin Oncol. 2019;37(31):2875-2882.

129. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 2003;21(10):2019-2025.

130. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21(3):203-212.

131. Dunkel IJ, Lee TC, Shi W, et al. A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer. 2007;49(5):643-648.

132. Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31(11):1458-1463.

133. Perez V, Sampor C, Rey G, et al. Treatment of Nonmetastatic Unilateral Retinoblastoma in Children. JAMA Ophthalmol. 2018;136(7): 747-752.

134. Chantada GL, Fandino AC, Guitter MR, et al. Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer. 2010;55(1):60-66.

135. Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29(10):700-704.

136. Dunkel IJ, Khakoo Y, Kernan NA, et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer. 2010;55(1):55-59.

137. Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. Journal of Clinical Oncology. 2015;33(27):2999-3007.

138. Zoubek A, Slavc I, Mann G, Trittenwein G, Gadner H. Natural course of a Wilms’ tumour. The Lancet. 1999;354(9175):344.

139. Pritchard-Jones K, Graf N, Tinteren Hv, Craft A. Evidence for a delay in diagnosis of Wilms’ tumour in the UK compared with Germany: implications for primary care for children. Arch Dis Child. 2016;101(5):417-420.

140. Grundy PE, Green DM, Dirks AC, et al. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatric blood & cancer. 2012;59(4):631-635.

141. Kalish JM, Doros L, Helman LJ, et al. Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. Clin Cancer Res. 2017;23(13):e115-e122.

142. Brioude F, Kalish JM, Mussa A, et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol. 2018;14(4):229-249.

143. Tournade MF, Com-Nougué C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms’ tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J Clin Oncol. 2001;19(2):488-500.

144. Pritchard-Jones K, Kelsey A, Vujanic G, et al. Older age is an adverse prognostic factor in stage I, favorable histology Wilms’ tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children’s Cancer Study Group, Wilm’s Tumor Working Group. J Clin Oncol. 2003;21(17):3269-3275.

145. Fernandez CV, Perlman EJ, Gastier-Foster J, et al. Reply to B. Zhang et al. J Clin Oncol. 2018;36(14):1454-1455.

146. Parsons LN, Mullen EA, Geller JI, et al. Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children’s Oncology Group study AREN03B2. Cancer. 2020.

147. Verschuur A, Van Tinteren H, Graf N, Bergeron C, Sandstedt B, de Kraker J. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. J Clin Oncol. 2012;30(28):3533-3539.

148. Pasqualini C, Furtwängler R, van Tinteren H, et al. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group. Eur J Cancer. 2020;128:38-46.

149. Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms’ tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am. 2000;27(3):443-454.

150. Vujanic GM, Gessler M, Ooms A, et al. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2018;15(11):693-701.

151. Dix DB, Fernandez CV, Chi YY, et al. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report. J Clin Oncol. 2019;37(30):2769-2777.

152. Mullen EA, Chi YY, Hibbitts E, et al. Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With FavorableHistology Wilms Tumor: A Report From the Children’s Oncology Group. J Clin Oncol. 2018:JCO1800076.

153. Brok J, Lopez-Yurda M, Tinteren HV, et al. Relapse of Wilms’ tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms’ tumour protocol database. Lancet Oncol. 2018;19(8):1072-1081.

154. van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, et al. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol. 2017;14(12):743-752.

155. van den Heuvel-Eibrink MM, Grundy P, Graf N, et al. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. Pediatr Blood Cancer. 2008;50(6):1130-1134.

156. Hessissen L, Parkes J, Amayiri N, et al. SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatric Blood & Cancer. 2018;64(S5):e26737.

157. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2641-2647.

158. Dodgshun AJ, Maixner WJ, Heath JA, Sullivan MJ, Hansford JR. Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy. Int J Cancer. 2016;138(2):481-488.

159. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747-754.

160. Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II Weekly Vinblastine for Chemotherapy-Naive Children With Progressive LowGrade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2016;34(29):3537-3543.

161. Filippi AR, Russi E, Magrini SM, Corvo R. Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. Int J Radiat Oncol Biol Phys. 2020.

162. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337.

163. Rivera A, Ohri N, Thomas E, Miller R, Knoll MA. The Impact of COVID-19 on Radiation Oncology Clinics and Cancer Patients in the U.S. Adv Radiat Oncol. 2020.

164. NICE Guidance. C-. COVID-19 rapid guideline:delivery of radiotherapy. In: https://www.nice.org.uk/guidance/NG162; 2020.

165. Slotman B, Ricardi, Umberto., Lievens, Yolande.,. “Radiotherapy in a time of crisis”, ESTRO Presidents statement. 2020; https://www.estro.org/About/Newsroom/News/Radiotherapy-in-a-time-of-crisis.

166. Simcock R, Thomas TV, Estes C, et al. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020;22:55-68.

167. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21(4):e181.

168. Krengli M, Ferrara, Eleonora., Mastroleo, Federico ., Brambilla,Marco ., Ricard, Umberto . Running a Radiation Oncology Department at the time of coronavirus: an Italian experience. Advances in Radiation Oncology. 2020;in press.

169. Achard V, Tsoutsou P, Zilli T. Radiotherapy in the time of the Coronavirus pandemic: when less is better. Int J Radiat Oncol Biol Phys. 2020.

170. Parkes J, Hess C, Burger H, et al. Recommendations for the treatment of children with radiotherapy in low‐ and middle‐income countries (LMIC): A position paper from the Pediatric Radiation Oncology Society (PROS‐LMIC) and Pediatric Oncology in Developing Countries (PODC) working groups of the International Society of Pediatric Oncology (SIOP). Pediatric Blood & Cancer. 2018;64(S5):e26903.

171. Stefan DC, Rodriguez-Galindo, Carlos.,. Paediatric Hematology-Oncology in Countries with Limited Resources A Practical Manual Springer; 2014.

172. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review. Plos One. 2012;7(4):e35797.

173. Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19. Anaesthesia. 2020.

174. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intens Care Med. 2020:1-34.

175. Ong S, Khee TT. Practical considerations in the anaesthetic management of patients during a COVID-19 epidemic. Anaesthesia. 2020.

176. Pryor A. SAGES AND EAES RECOMMENDATIONS REGARDING SURGICAL RESPONSE TO COVID-19 CRISIS. . 2020; https://www.sages.org/recommendations-surgical-response-covid-19/. Accessed 6 April 2020, 2020.

177. Spinelli A, Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. Br J Surg. 2020.

178. Solinas G, Platini F, Trivellato M, Rigo C, Alabiso O, Galetto AS. Port in oncology practice: 3-monthly locking with normal saline for catheter maintenance, a preliminary report. J Vasc Access. 2017;18(4):325-327.

179. Powell RA, Schwartz L, Nouvet E, et al. Palliative care in humanitarian crises: always something to offer. Lancet. 2017;389(10078):1498-1499.

180. Weaver MS, Heinze KE, Kelly KP, et al. Palliative Care as a Standard of Care in Pediatric Oncology. Pediatr Blood Cancer. 2015;62 Suppl 5(Suppl 5):S829-833.

181. Wolfe J, Hammel JF, Edwards KE, et al. Easing of suffering in children with cancer at the end of life: is care changing? J Clin Oncol. 2008;26(10):1717-1723.

182. Wolfe J, Orellana L, Ullrich C, et al. Symptoms and Distress in Children With Advanced Cancer: Prospective Patient-Reported Outcomes From the PediQUEST Study. J Clin Oncol. 2015;33(17):1928-1935.

183. Kreicbergs U, Valdimarsdóttir U, Onelöv E, Henter JI, Steineck G. Talking about death with children who have severe malignant disease. N Engl J Med. 2004;351(12):1175-1186.

184. Mack JW, Cronin AM, Kang TI. Decisional Regret Among Parents of Children With Cancer. J Clin Oncol. 2016;34(33):4023-4029.

185. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics. 2020:e20200702.

186. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020;55(5):1169-1174.

187. St Jude Global C-OaRC. The Global COVID-19 Observatory and Resource Center for Childhood Cancer. 2020; https://global.stjude.org/en-us/global-covid-19-observatory-and-resource-center-for-childhood-cancer.html. Accessed 22 April, 2020.

188. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State. J Pediatric Infect Dis Soc. 2019;8(1):21-28.

189. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.

190. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020.

191. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.

192. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127(22):2682-2692.

193. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929-936.

194. Tang YW, Schmitz JE, Persing DH, Stratton CW. The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges. J Clin Microbiol. 2020.

195. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502-505.

196. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020.

197. Global COVID-19 Registry. St Jude Childrens Research Hospital; 2020. https://global.stjude.org/en-us/global-covid-19-observatory-andresource-center-for-childhood-cancer.html. Accessed 22 April 2020.